Tezspire approved in Japan for severe asthma
27 September 2022 07:00 BST Tezspire approved in Japan for the treatment of severe asthma Tezspire approved for a broad population of patients with severe asthmawith no phenotype or biomarker limitations AstraZeneca's Tezspire (tezepelumab) has been approved in Japan for the treatment of bronchial asthma in patients with severe or refractory disease in whom asthma symptoms cannot be controlled with mid- or high-dose inhaled corticosteroids and other long-term maintenance therapies.[1] The approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) was based on